SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart (JACC: Basic to Translational Science February 2019) is organized by American College of Cardiology (ACC).
Date of Release: February 25, 2019
Term of Approval/Date of CME/MOC/ECME Expiration: February 25, 2020
JACC Journal CME/MOC is intended for physicians who treat patients with cardiovascular disease.
Recent landmark cardiovascular outcome trials (EMPA-REG OUTCOME [Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients] and CANVAS [Canagliflozin Cardiovascular Assessment Study]) have revealed an unexpected cardiovascular mortality benefit from sodium/glucose cotransporter 2 (SGLT2) inhibition in patients with diabetes mellitus with high cardiovascular risk. We hypothesized that some of this benefit is derived through attenuation of ischemia/reperfusion injury, independent of glycemic status.
After reading this article the reader should be able to:
• Discuss the effects of treatment with canagliflozin on myocardial infarct size among Zucker Diabetic Fatty (ZDF) rats with diabetes mellitus and Zucker Lean (ZL) rats without diabetes mellitus.
• Examine the guideline recommendations for prevention of acute myocardial infarction in patients with diabetes mellitus.
• Define the potential applications of canagliflozin on cardiovascular health among people with or at risk of cardiovascular disease.
Additional details will be posted as soon as they are available.